Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every…
Brook StarRay Wireless Controller Now Available — Native PS5 Support Meets Xbox-Style Control
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight
Scalare Launches EquityRoom, Adding a Subscription Revenue Stream to Its Founder Ecosystem
Megaannum Capital and Zhongke Xianxing Venture Capital Enter into Strategic Partnership